Cargando…
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Adoptive cell therapy has received a great deal of interest in the treatment of advanced cancers that are resistant to traditional therapy. The tremendous success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells in the treatment of cancer, especially hematological cancers, has exposed C...
Autores principales: | Marofi, Faroogh, Saleh, Marwan Mahmood, Rahman, Heshu Sulaiman, Suksatan, Wanich, Al-Gazally, Moaed E., Abdelbasset, Walid Kamal, Thangavelu, Lakshmi, Yumashev, Alexei Valerievich, Hassanzadeh, Ali, Yazdanifar, Mahboubeh, Motavalli, Roza, Pathak, Yashwant, Naimi, Adel, Baradaran, Behzad, Nikoo, Marzieh, Khiavi, Farhad Motavalli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252313/ https://www.ncbi.nlm.nih.gov/pubmed/34215336 http://dx.doi.org/10.1186/s13287-021-02462-y |
Ejemplares similares
-
A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine
por: Moghadasi, Soudeh, et al.
Publicado: (2021) -
A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
por: Razeghian, Ehsan, et al.
Publicado: (2021) -
A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
por: Marofi, Faroogh, et al.
Publicado: (2021) -
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
por: Marofi, Faroogh, et al.
Publicado: (2021) -
Correction to: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
por: Marofi, Faroogh, et al.
Publicado: (2021)